Fennec Pharmaceuticals Inc experiences a notable week of price movement as it prepares for significant clinical presentations.
Fennec Pharmaceuticals Inc (FRX.TO) has seen a mixed week on the TSX, closing the last trading session at C$15.00, marking a slight increase of 1.31% for the day. However, the stock has faced a decline of 13.92% over the past week and 13.46% over the month, despite a year-to-date increase of 41.40%. This volatility comes amid recent announcements regarding clinical study results and financial performance.
Investor takeaway: Investors should consider the implications of Fennec's recent clinical study results and financial performance as the company continues to navigate the competitive landscape of the health care sector.
Advertisement
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$516.19M
52W high
$17.64
52W low
$7.59
1W change
-13.92%
Beta
1.10
Analyst Price Targets
Based on analyst covering FRX · as of Sep 17, 2026
Wall Street analysts forecast FRX stock price to rise 535.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+535.7% Upside
Current Price
C$14.72
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
82.1%
Annualized
90-Day Vol
80.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$17.93
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$15.92 | C$11.99 – C$21.14 |
| 60 trading days | C$16.90 | C$11.32 – C$25.23 |
| 90 trading days | C$17.93 | C$10.98 – C$29.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Fennec Pharmaceuticals Reports 78% Increase in Q2 Sales
The company's net product sales reached $17.1 million for the second quarter of 2026, reflecting strong market demand and operational growth.
Bull case
The recent oral presentation of Phase 2 STS-J01 study results at SIOP 2026 showed a significant reduction in hearing loss among patients. This positive outcome could boost demand for PEDMARK® and strengthen the company's position in the market.
Bear case
Despite the encouraging study results, the stock's recent decline and low trading volume compared to the 20-day average may signal caution among investors amid ongoing market volatility.
Recent Company News
Fennec Pharmaceuticals recently announced an oral presentation of the Phase 2 STS-J01 study results at the SIOP 2026 conference. The study met its primary endpoint, showing that only 24% of patients experienced hearing loss, significantly lower than the historical benchmark of 56.4% (P=0.001). Additionally, 84% of patients had Grade 0 hearing loss by Brock criteria, with no Grade 3 or 4 hearing loss observed. This positive outcome could enhance the company's reputation and demand for its drug, PEDMARK®.
Financial Performance Highlights
Advertisement
In its second quarter of 2026, Fennec Pharmaceuticals reported net product sales of $17.1 million, marking an impressive 78% year-over-year increase. The company also achieved a non-GAAP adjusted EBITDA of $2.8 million. Management attributed the growth to strong demand for PEDMARK® and the expansion of their field sales efforts, signaling a positive trend in commercial growth.
Technical Picture
Fennec Pharmaceuticals' stock is currently trading at C$15.00, which is 4.0% below its 50-day moving average of C$15.62 and 23.6% above its 200-day moving average of C$12.13. The stock has a beta of 1.10, indicating slightly higher volatility compared to the broader market. The 52-week range for the stock is C$7.59 to C$17.64, suggesting that it is currently trading at 74% of its range. The latest trading volume was 112 shares, significantly lower than the 20-day average volume of 1,235 shares, reflecting a cautious market sentiment.
Insider Activity
No recent insider activity has been reported for Fennec Pharmaceuticals, indicating that there have been no significant changes in insider ownership or new acquisitions by company executives.
Price Action Summary
Fennec Pharmaceuticals Inc closed at C$15.00, marking a 1.31% increase for the day. However, the stock has seen a decline of 13.92% over the past week, highlighting the volatility in its recent performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
